Conclusion
The survival gain in patients with bone metastases from CRPC treated
with 223Ra is well established, but the identification
of baseline variables that may predict the individual response to
treatment is a continuous challenge. In our analysis, the baseline QoL
assessed through the EORTCÂ QLQ-C30 and the EORTC QLQ-BM22, showed a
significant correlation with OS, meaning that patients with better
baseline QoL are more likely to obtain a marked survival prolonging
effect from 223Ra-therapy. These findings suggest that
patient-reported QoL measures, in addition to clinic-pathological
factors, may improve prognostic stratification in mCRPC patients
undergoing 223Ra-therapy, thus influencing clinical
decision-making process and patient-doctor communication about
prognosis.